Herpes viruses and tumours in kidney transplant recipients. the role of immunosuppression

Nephrology Dialysis Transplantation

Volumn 26, Issue 6, 2011, Pages 1769-1775

  Ponticelli, Claudio ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

herpes viruses; immunosuppression; oncogenis viruses; renal transplantation; tumours

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN; EPSTEIN BARR VIRUS ANTIGEN 1; EVEROLIMUS; GANCICLOVIR; INTERLEUKIN 6; LATENT MEMBRANE PROTEIN 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STAT PROTEIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ANEMIA; ANOREXIA; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL GROWTH; CELL PROLIFERATION; CLINICAL FEATURE; COLON CANCER; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS INFECTION; ETHNICITY; FEVER; GRAFT RECIPIENT; HEADACHE; HERPES VIRUS INFECTION; HUMAN; HUMAN HERPESVIRUS 8; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION RISK; KAPOSI SARCOMA; KIDNEY TRANSPLANTATION; KIDNEY TUMOR; LEUKOPENIA; LYMPHOCYTE DEPLETION; LYMPHOCYTOSIS; LYMPHOPROLIFERATIVE DISEASE; MALAISE; MYALGIA; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; POST TRANSPLANT LYMPHOPROLIFERATIVE DISEASE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; VIRUS REACTIVATION; VIRUS REPLICATION;

EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; NEOPLASMS;

EID: 79958166689     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr157     Document Type: Review

References (84)

1. Grulich AE, van Leeuwen MT, Falster MO et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370: 59-67. (Pubitemid 47017468)
2. Sagedal S, Nordal KP, Hartmann A et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002; 2: 850-856. (Pubitemid 36306840)
3. McLaughlin K, Wu C, Fick G et al. A Cytomegalovirus serum mismatching increases the risk of acute renal allograft rejection. Transplantation 2002; 74: 813-816.
4. Reischig T, Jindra P, Hes O et al. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis. Transplantation 2009; 87: 436-444.
5. Smith JM, Corey L, Bittner R et al. Subclinical viremia increases risk for chronic allograft injury in pediatric renal transplantation. J Am Soc Nephrol 2010; 21: 1579-1586.
6. Blum A, Peleg A, Weinberg M. Anti-cytomegalovirus (CMV) IgG antibody titer in patients with risk factors for atherosclerosis. Clin Exp Med 2003; 3: 157-160. (Pubitemid 37491545)
7. Streblow DN, Dumortier J, Moses AV et al. Mechanisms of cytomegalovirus-accelerated vascular disease: induction of paracrine factors that promote angiogenesis andwound healing. Curr Top Microbiol Immunol 2008; 325: 397-415.
8. Slinger E, Maussang D, Schreiber A et al. HCMV-encoded chemokine receptor US28 mediates proliferative signaling through the IL-6- STAT3 axis. Sci Signal 2010; 3: ra58.
9. Maussang D, Verzijl D, van Walsum M et al. Human cytomegalovirus- encoded chemokine receptor US28 promotes tumorigenesis. Proc Natl Acad Sci USA 2006; 103: 13068-13073. (Pubitemid 44338917)
10. Bongers G, Maussang D, Muniz LR et al. The cytomegalovirusencoded chemokine receptor US28 promotes intestinal neoplasia in transgenic mice. J Clin Invest 2010; 120: 3969-3978.
11. Cinatl JJr., Vogel JU, Kotchetkov R et al. Oncomodulatory signals by regulatory proteins encoded by human cytomegalovirus: a novel role for viral infection in tumor progression. FEMS Microbiol Rev 2004; 28: 59-77. (Pubitemid 38224507)
12. Streblow DN, Vomaske J, Smith P et al. Human cytomegalovirus chemokine receptor US28-induced smooth muscle cell migration is mediated by focal adhesion kinase and Src. J Biol Chem 2003; 278: 50456-50465. (Pubitemid 37548891)
13. Odeberg J, Browne H, Metkar S et al. The human cytomegalovirus protein UL16 mediates increased resistance to natural killer cell cytotoxicity through resistance to cytolytic proteins. J Virol 2003; 77: 4539-4545. (Pubitemid 36406375)
14. Harkins L, Volk AL, Samanta M et al. Specific localisation of human cytomegalovirus nucleic acids and proteins in human colorectal cancer. Lancet 2002; 360: 1557-1563. (Pubitemid 35356371)
15. Hoever G, Vogel JU, Lukashenko P et al. Impact of persistent cytomegalovirus infection on human neuroblastoma cell gene expression. Biochem Biophys Res Commun 2005; 326: 395-401. (Pubitemid 39593560)
16. Samanta M, Harkins L, Klemm K et al. High prevalence prevalence of human cytomegalovirus in prostatic intraepithelial neoplasia and prostatic carcinoma. J Urol 2003; 170: 998-1002. (Pubitemid 36999620)
17. Söderberg-Nauclér C. HCMV microinfections in inflammatory diseases and cancer. J Clin Virol 2008; 41: 218-223.
18. Michaelis M, Doerr HW, Cinatl J Jr. The Story of Human Cytomegalovirus and Cancer: Increasing Evidence and Open Questions. Neoplasia 2009; 11: 1-9.
19. Charpentier B, Rostaing L, Berthoux F et al. A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. Transplantation 2003; 75: 844-851. (Pubitemid 36373458)
20. Tian JH, Wang X, Yang KH et al. Induction with and without antithymocyte globulin combined with cyclosporine/tacrolimus-based immunosuppression in renal transplantation: a meta-analysis of randomized controlled trials. Transplant Proc 2009; 41: 3671-3676.
21. Kode RK, Kumar AM, Pankewycz O et al. Simulect induction significantly decreases CMV infection in kidney recipients compared to OKT3. Transplant Proc 2001; 33: 1268-1279.
22. Margreiter R, Klempnauer J, Neuhaus P et al. Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial. Am J Transplant 2008; 8: 1480-1485. (Pubitemid 351989498)
23. Vincenti F, Kirkman R, Light S et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 1998; 338: 161-165. (Pubitemid 28041863)
24. Ponticelli C, Yussim A, Cambi V et al. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Transplantation 2001; 72: 1261-1267. (Pubitemid 33026606)
25. Webster AC, Ruster LP, McGee R et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev 2010; 1 CD003897.
26. Webster AC,Woodroffe RC, Taylor RS et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 2005; 331: 810.
27. Basic-Jukic N, Kes P, Bubic-Filipi LJ et al. Does mycophenolate mofetil increase the incidence of cytomegalovirus disease compared with azathioprine after cadaveric kidney transplantation?. Transplant Proc 2005; 37: 850-851. (Pubitemid 40590722)
28. Giral M, Nguyen JM, Daguin P et al. Mycophenolate mofetil does not modify the incidence of cytomegalovirus (CMV) disease after kidney transplantation but prevents CMV-induced chronic graft dysfunction. J Am Soc Nephrol 2001; 12: 1758-1763. (Pubitemid 32674440)
29. Johnson RA, Wang X, Ma XL et al. Human cytomegalovirus upregulates the phosphatidylinositol 3-kinase (PI3-K) pathway: inhibition of PI3-K activity inhibits viral replication and virus-induced signaling. J Virol 2001; 75: 6022-6032. (Pubitemid 32553133)
30. Kudchodkar SB, Yu Y, Maguire TG et al. Human cytomegalovirus infection induces rapamycin-insensitive phosphorylation of downstream effectors of mTOR kinase. J Virol 2004; 78: 11030-11039. (Pubitemid 39299643)
31. Kudchodkar SB, Yu Y, Maguire TG et al. Human cytomegalovirus infection alters the substrate specificities and rapamycin sensitivities of raptor- and rictor-containing complexes. Proc Natl Acad Sci USA 2006; 103: 14182-14187. (Pubitemid 44453000)
32. Araki K, Turner AP, Shaffer VO et al. mTOR regulates memory CD8 T-cell differentiation. Nature 2009; 460: 108-112.
33. Eisen HJ, Tuzcu EM, Dorent R et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847-858. (Pubitemid 37025404)
34. Viganò M, Dengler T, Mattei MF et al. Study Investigators. Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study. Transpl Infect Dis 2010; 12: 23-30.
35. Webster AC, Lee VW, Chapman JR et al. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 2006; 81: 1234-1248.
36. Mañez R, Breinig MC, Linden P et al. Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease. J Infect Dis 1997; 176: 1462-1467. (Pubitemid 27518144)
37. Walker RC, Marshall WF, Strickler JG et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995; 20: 1346-1353.
38. Opelz G, Daniel V, Naujokat C et al. Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma: a multicentre retrospective analysis. Lancet Oncol 2007; 8: 212-218. (Pubitemid 46291703)
39. Opelz G, Daniel V, Naujokat C et al. Epidemiology of pretransplant EBV and CMV serostatus in relation to posttransplant non-Hodgkin lymphoma. Transplantation 2009; 88: 962-967.
40. Couzi L, Levaillant Y, Jamai A et al. Cytomegalovirus-induced γδ T cells associate with reduced cancer risk after kidney transplantation. J Am Soc Nephrol 2010; 21: 181-188.
41. Söderberg-Nauclér C. Protection from cancer in kidney transplant patients by γδ T cells: Role of CMV infection?. J Am Soc Nephrol 2010; 21: 11-13.
42. Kauffman HM, Cherikh WS, Cheng Y et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005; 80: 883-889. (Pubitemid 41552882)
43. Campe H, Jaeger G, Abu-Ajram C et al. Serial detection of Epstein- Barr virus DNA in sera and peripheral blood lymphocyte samples of pediatric renal allograft recipients with persistent mononucleosis-like symptoms defines patients at risk to develop lymphoproliferative disease. Pediatr Transplant 2003; 7: 46-52. (Pubitemid 36314190)
44. Cohen JI. Epstein-Barr virus and the immune system. Hide and seek. JAMA 1997; 278: 510-513. (Pubitemid 27344006)
45. Moore KW, Vieira P, Fiorentino DF et al. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRF1. Science 1990; 248: 1230-1234.
46. Luzuriaga K, Sullivan JL. Infectious mononucleosis. N Engl J Med 2010; 362: 1993-2000.
47. Birkeland SA, Bendtzen K, Møller B et al. Interleukin-10 and posttransplant lymphoproliferative disorder after kidney transplantation. Transplantation 1999; 67: 876-881. (Pubitemid 29169134)
48. Muti G, Cantoni S, Oreste P et al. Cooperative Study Group on PTLDs. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment. Haematologica 2002; 87: 67-77. (Pubitemid 34101115)
49. Gottschalck S, Rooney CM, Heslop H. Post-transplant lymphoproliferative disorders. Annu Rev Med 2005; 56: 29-44. (Pubitemid 40299772)
50. Blaes AH, MorrisonVA. Post-transplant lymphoproliferative disorders following solid-organ transplantation. Expert Rev Hematol 2010; 3: 35-44.
51. Cherikh WS, Kauffman HM, McBride MA et al. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003; 76: 1289-1293. (Pubitemid 37430713)
52. Bustami RT, Ojo AO, Wolfe RA et al. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant 2004; 4: 87-93. (Pubitemid 38155493)
53. Opelz G, Naujokat C, Daniel V et al. Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation 2006; 81: 1227-1233. (Pubitemid 43804539)
54. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report.AmJ Transplant 2004; 4: 222-230. (Pubitemid 38248525)
55. Boyle GJ, Michaels MG, Webber SA et al. Posttransplantation lymphoproliferative disorders in pediatric thoracic organ recipients. J Pediatr 1997; 131: 309-313. (Pubitemid 27495257)
56. Penn I. Cancers following cyclosporine therapy. Transplantation 1987; 43: 32-35. (Pubitemid 17002451)
57. Caillard S, Dharnidharka V, Agodoa L et al. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005; 80: 1233-1243. (Pubitemid 41746802)
58. Robson R, Cecka JM, Opelz G et al. Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant 2005; 5: 2954-2960. (Pubitemid 43923957)
59. Vincenti F, Charpentier B, Vanrenterghem Y et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535-546.
60. Geissler EK, Schlitt HJ, Thomas G. mTOR, cancer and transplantation. Am J Transplant 2008; 8: 2212-2218.
61. Majewski M, Korecka M, Joergensen J et al. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograftprotecting doses. Transplantation 2003; 75: 1701-1707.
62. Nepomuceno RR, Balatoni CE, Natkunam Y et al. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas. Cancer Res 2003; 63: 4472-4480. (Pubitemid 36951019)
63. Vaysberg M, Balatoni CE, Nepomuceno RR et al. Rapamycin inhibits proliferation of Epstein-Barr virus-positive B-cell lymphomas through modulation of cell-cycle protein expression. Transplantation 2007; 83: 1114-1121. (Pubitemid 46659124)
64. Coiffier B, Ribrag V. Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies. Leuk Lymphoma 2009; 50: 1916-1930.
65. Zaltzman JS, Prasad R, Chun K et al. Resolution of renal allograftassociated post-transplant lymphoproliferative disorder with the introduction of sirolimus. Nephrol Dial Transplant 2005; 20: 1748-1751. (Pubitemid 41418607)
66. Boraty?ska M, Smolska D. Inhibition of mTOR by sirolimus induces remission of post-transplant lymphoproliferative disorders. Transpl Int 2008; 21: 605-608. (Pubitemid 351600070)
67. Ong KW, Teo M, Lee V et al. Expression of EBV latent antigens, mammalian target of rapamycin, and tumor suppression genes in EBV-positive smooth muscle tumors: clinical and therapeutic implications. Clin Cancer Res 2009; 15: 5350-5358.
68. McDonald RA, Smith JM, Ho M et al. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant 2008; 8: 984-989. (Pubitemid 351537758)
69. Hennge UR, Ruzicka T, Tyring SK et al. Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 2: Pathogenesis, Castleman's disease and pleural effusion lymphoma. Lancet Infect Dis 2002; 2: 344-352. (Pubitemid 34595974)
70. Rabkin CS, Janz S, Lash A et al. Monoclonal origin of multicentric Kaposi's sarcoma lesions. N Engl J Med 1997; 336: 988-993. (Pubitemid 27152784)
71. Montaner S. Akt/TSC/mTOR activation by the KSHV G proteincoupled receptor: emerging insights into the molecular oncogenesis and treatment of Kaposi's sarcoma. Cell Cycle 2007; 6: 438-443. (Pubitemid 46393447)
72. Tan HH, Goh CL. Viral infections affecting the skin in organ transplant recipients: epidemiology and current management strategies. Am J Clin Dermatol 2006; 7: 13-29.
73. Cattani P, Capuano M, Graffeo R et al. Kaposi's sarcoma associated with previous human herpes virus 8 infection in kidney transplant recipients. J Clin Microbiol 2001; 39: 506-508. (Pubitemid 32150808)
74. Regamey N, Tamm M, Wernli M et al. Transmission of human herpesvirus 8 from renal transplant donors to recipients. N Engl J Med 1998; 339: 1358-1363.
75. Mantovani A, Savino A, Locati M et al. The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev 2010; 21: 27-39.
76. Mbulaiteye SM, Engels EA. Kaposi's sarcoma risk among transplant recipients in the United States (1993-2003). Int J Cancer 2006; 119: 2685-2691. (Pubitemid 44691326)
77. Penn I. Kaposi's sarcoma in transplant recipients. Transplantation 1997; 64: 669-673. (Pubitemid 27407090)
78. Lebbé C, Legendre C, Francès C. Kaposi sarcoma in transplantation. Transplant Rev 2008; 22: 252-261.
79. Doutrelepont JM, De Pauw L, Gruber SA et al. Renal transplantation exposes patients with previous Kaposi's sarcoma to a high risk of recurrence. Transplantation 1996; 62: 463-466. (Pubitemid 26295820)
80. Campistol JM, Gutierrez-Dalmau A, Torregrosa JV. Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma. Transplantation 2004; 77: 760-762. (Pubitemid 38366986)
81. Stallone G, Schena A, Infante B et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2006; 352: 1317-1323.
82. Mohsin N, Budruddin M, Pakkyara A et al. Complete regression of visceral Kaposi's sarcoma after conversion to sirolimus. Exp Clin Transplant 2005; 3: 366-369.
83. Descoeudres B, Giannini O, Graf T et al. No effect of sirolimus for Kaposi sarcoma in a renal transplant recipient. Transplantation 2006; 81: 1472-1474. (Pubitemid 43847162)
84. Carbone A, Gloghini A. KSHV/HHV8-associated lymphomas. Br J Haematol 2008; 140: 13-24 (Pubitemid 350233250)